Kling Douglas F 4
4 · NewAmsterdam Pharma Co N.V. · Filed May 19, 2025
Insider Transaction Report
Form 4
Kling Douglas F
Chief Operating Officer
Transactions
- Sale
Ordinary Shares
2025-05-15−100,000→ 44,000 total - Exercise/Conversion
Ordinary Shares
2025-05-15$10.00/sh+100,000$1,000,000→ 144,000 total - Exercise/Conversion
Option (right to buy)
2025-05-15−100,000→ 450,930 totalExercise: $10.00Exp: 2032-11-22→ Ordinary Shares (100,000 underlying)
Footnotes (3)
- [F1]This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- [F2]These shares were sold in multiple transactions at prices ranging from $18.38 per share to $18.89 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
- [F3]The option was granted on November 22, 2022. The shares underlying the option vest in equal monthly installments over four years, with the first 1/48th of such shares vesting on December 22, 2022 and the remaining installments vesting on each one-month anniversary of the grant date, subject to the Reporting Person's continued service through each such date.